Mark Breidenbach
Stock Analyst at Oppenheimer
(1.67)
# 3,444
Out of 5,146 analysts
48
Total ratings
30.91%
Success rate
0.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $2.73 | +156.41% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $16.11 | +86.22% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $13.38 | +610.01% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $4.99 | +401.00% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.29 | +3,373.43% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $8.88 | +2,602.70% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.88 | +5,455.56% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.79 | +291.06% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.99 | +1,508.04% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $3.79 | +295.78% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.03 | +946,501.94% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $2.73
Upside: +156.41%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $16.11
Upside: +86.22%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $13.38
Upside: +610.01%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $4.99
Upside: +401.00%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.29
Upside: +3,373.43%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $8.88
Upside: +2,602.70%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.88
Upside: +5,455.56%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.79
Upside: +291.06%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.99
Upside: +1,508.04%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $3.79
Upside: +295.78%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.03
Upside: +946,501.94%